Table 4.
IVIG products for replacement therapy in primary immunodeficiency available in the United States in 2010
| Product | Form | Stabilizer/Sugar | IgA (μg/ml) | Osm (mOsm/kg or L) | Sodium (mg/ml) | Storage | Manufacturer |
|---|---|---|---|---|---|---|---|
| Carimune | Lyophilized | Sucrose | Trace | 768 (12%) | <2.4 | RT (24 m) | CSL |
| Flebogamma | 5% liquid | Sorbitol | <50 | 240–370 | ? | RT (24 m) | Griffols |
| Gammagard liquid | 10% liquid | Glycine | 37 | 240–300 | None added | RT (6 m) 4° (36 m) |
Baxter |
| Gammagard SD | Lyophilized | Glucose | <2.2 | 1250 (10%) | 8.5 | RT (24 m) | Baxter |
| Gammunex | 10% liquid | Glycine | 46 | 258 | Trace | RT (9 m) 4° (36 m) |
Talecris |
| Octagam | 5% liquid | Maltose | <200 | 310–380 | <0.7 | RT (24 m) | Octapharma |
| Privigen | 10% liquid | Proline | <25 | 240–440 | Trace | RT (24 m) | CSL |
Abbreviation: RT, room temperature.